Vnitřní lékařství 4/2020

PŘEHLEDOVÉ ČLÁNKY Krvácení do GIT při portální hypertenzi | E15  / Vnitř Lék 2020; 66(2): e7–e16  /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Šafka V. Portální hypertenze, patofyziologie portální hypertenze In: Hůlek P, Urbánek P (eds.). Hepatologie, 3. vydání. Praha: Grada 2018, 180–181. 2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. 3. Fejfar T, Vaňásek T, Brůha R, et al. Léčba krvácení v důsledku portální hypertenze při jaterní cirhóze - aktualizace doporučených postupů ČHS ČLS JEP. Gastroent Hepatol 2017; 71: 105–116. 4. De Franchis R, Baveno VI. Faculty Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015 ;63: 743–752. 5. De Francis R et al. Portal hypertension IV: Proceedings of the Fourth Baveno Internati‑ onal Konsensus Workshop. Blackwell Publishing Ltd., 2006. 6. De Franchis R, et al. Portal Hypertension V: Proceedings of the Fifth Baveno Internatio‑ nal Consensus Workshop, 5 th Edition. Wiley-Blackwell press. London; 2011. 7. North Italian Endoscopic Club for Study and Treatment of Esophageal Varices. Predicti‑ on of the first variceal haemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicentre study. N Engl J Med 1988; 319: 983. 8. D’Amico G, Pasta L, Morabito A et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39: 1180–1193. 9. Augustin S, Muntaner L, Altamirano JT, et al. Predicting early mortality after acute va‑ riceal hemorrhage based on classification and regression tree analysis. Clin Gastroente‑ rol Hepatol 2009; 7: 1347–1354. 10. Carbonell N, Pauwels A. Sarfaty L, et al. Improved survival after variceal bleeding in pa‑ tients with cirrhosis over the past two decades. Hepatology 2004; 40: 652–659. 11. Villanueva C, Colomo A, Bosch et al. Transfusion strategies for acute upper gastroin‑ testinal bleeding. N Engl J Med 2013; 368: 11–21. 12. Bosch J, Thabut D, Albillos A et al. Recombinant factor VIIa for variceal bleeding in pati‑ ents with advanced cirrhosis: A randomised, controlled trial. Hepatology 2008; 47: 1604–1614. 13. Bendtsen F, D´Amico G, Rusch E, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014; 61: 252–259. 14. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepa‑ tology 1998; 27: 1207–1212. 15. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bac‑ terial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. He‑ patology 1999; 29: 1655–1661. 16. Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis for cirrhotic pa‑ tients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002; 2: CD002907. 17. Chavez-TapiaNC,Barrientos-GutierrezT,Tellez-AvilaFI,etal.Antibioticprophylaxis forcirrho‑ ticpatientswithuppergastrointestinalbleeding.CochraneDatabaseSystRev2010;8:CD002907. 18. Hůlek P, Krajina A (eds.). Current Practice of TIPS. Hradec Králové: Published by Olga Štambergová 2001 19. Brůha R, Mareček Z, Procházka V, et al. Double-Blind Randomized Multicenter Study Comparing the Efficacy and Safety of 10-Day to 5.Day Terlipressin Treatment of Bleeding Esophageal Varices. Hepato-Gastroenterology 2009; 56: 390–394. 20. Merkel C, Gatta A, Bolognesi M, et al. Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrho‑ sis. Dig Dis Sci 1988; 33: 1103–1109. 21. Møller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effect of ter‑ lipressin in portal hypertensive patients. Liver 2000; 20: 51–59. 22. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrh‑ age. Cochrane Database Syst Rev 2003; 1: CD002147. 23. Wells M, Chande N, Adams P. Meta-analysis: vasoactive medications for the manage‑ ment of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35: 1267–1278. 24. Yim SY, Seo YS, Jung CH, et al. Risk Factors for Developing Hyponatremia During Ter‑ lipressin Treatment: A Retrospective Analyses in Variceal Bleeding. J Clin Gastroenterol 2015; 49: 607–612. 25. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of so‑ matostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investi‑ gation. Hepatology 1995; 22: 106–111. 26. Moitinho E, Planas R, Banares R et al. Multicenter randomised controlled trial com‑ paring different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712–718. 27. Vilanueva C, Planella M, Arycil C, et al. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual soma‑ tostatin dose. Am J Gastroenterol 2005; 100: 624–630. 28. Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepato‑ logy 2014; 60: 954–963. 29. Svoboda P, Konečný M, Martínek A, et al. Acute upper gastrointestinal bleeding in li‑ ver cirrhosis patients. Biomedical Papers 2012; 165: 266–270. 30. D'Amico G, Pietrosi G, Tarantino I, et al. Emergency sclerotherapy versus vasoacti‑ ve drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277–1291. 31. D’Amico G, Pagliaro L, Pietrosi G, et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhotic patients: a Cochrane meta-analysis. Cochrane Da‑ tabase Syst Rev 2010; 3: CD002233. 32. Gralnek IM, Dumonceau JM, Kuipers JE, et al. Diagnosis and management of nonvari‑ ceal uppergastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: 1–46. 33. Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25: 1101–1104. 34. Villanueva C, Piqueras M, Aracil C, at al. A randomized controlled trial comparing li‑ gation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006; 45: 560–567. 35. Vaňásek T. Endoskopické diagnostické a terapeutické metody. In: Hepatologie, 1. vy‑ dání. Praha: Grada Publishing 2010, 88–99. 36. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guide‑ line by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014; 61: 642–659. 37. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the Eu‑ ropean Association for the Study of the Liver. Hepatology 2014; 60: 715–735. 38. Banares R, Albilos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharma‑ cologic treatment for acute variceal bleeding: ameta-analysis. Hepatology 2002; 35: 609–615. 39. Abraldes JG, Vilanueva C, Banares R, et al. Hepatic venous pressure gradient and progno‑ sis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48: 229–236. 40. D´Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Posttherapeutic out‑ come and prognostic indicators. Hepatology 2003; 38: 599–612. 41. Cardenas A, Gines P, Uritz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors and short-term prognosis. Hepa‑ tology 2001; 34: 671–676. 42. Avgerinos A, Armonis A. Balloon tamponade technique and efficacy in variceal hae‑ morrhage. Scand J Gastroenterol 1994; 29: (Suppl. 207): 11–16. 43. Zehetner J, Shamiyeh A, Wayand W, et al. Results of a new method to stop acute bleeding from esophageal varices: implantation of a self-expanding stent. Surg Endosc 2008; 22: 149–152. 44. Wright G, Lewis H, Hogan B, et al. A self-expanding metal stent for complicated va‑ riceal hemorrhage: experience at a single center. Gastrointest Endosc 2010; 71: 71–78. 45. Fejfar T, Šafka V, Jirkovský V, et al. Danišův jícnový stent v terapii varikózního krvácení. Gastroent Hepatol 2013; 67: 98–103. 46. Escorsell À, Pavel O, Cárdenas A, et al Variceal Bleeding Study Group. Esophageal ballo‑ on tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016; 63: 1957–1967. 47. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjuglar intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gas‑ troenterology 1996; 111: 138–146. 48. Chau TN, Patch D, Chan YW, et al. “Salvage“ transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114: 981–987. 49. Krajina A, Hulek P, Fejfar T, et al. Quality improvement guidelines for Transjugular In‑ trahepatic Portosystemic shunt (TIPS). Cardiovasc Intervent Radiol 2012; 35: 1295–1300. 50. Gluud LL, Krag A Banding ligation versus beta-blockers for primary prevention of oe‑ sophageal verices in adults. Cochrane Database Syst Rev 2012; 8: CD004544. 51. Drastich P, Lata J, Petrtýl J, et al. Endoscopic variceal band ligation compared with pro‑ pranolol for prophylaxis of first variceal bleeding. Annals of Hepatology 2011; 10: 142–149. 52. Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liv Intern 2014; 34: 655–667. 53. Ohnishi K, Nakayama T, Saito M et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985; 80: 132–135. 54. Mastai R, Bosch J, Navasa M, et al. Effects of alpha-adrenergic stimulation and beta‑ -adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4: 71–79. 55. Sinagra E, Perricone G, D´Amico M, et. al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther 2014; 39: 557–568. 56. Akbas H, Ozden M, Kanko M, et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 2005; 33: 528–536.